GlassScriptPhysician profile
James R Grua
NPI 1134159288
$15,512.76
in general payments reported to CMS, 2019-2025
44 companies · $447 in 2025
The $447 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $1,067 · 2021: $3,610 · 2022: $8,300 · 2023: $732 · 2024: $185 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348 · Entertainment: $15.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.06 |
| Entertainment | $15.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amryt Pharma Holdings LTD | $7,443.26 | 2021-2023 | Myalept, Mycapssa |
| Recordati_rare_diseases_inc. | $2,550.65 | 2021 | |
| Amgen INC. | $1,516.19 | 2019-2025 | Evenity, Prolia, Prolia |
| Ascendis Pharma Endocrinology INC | $714.18 | 2022-2025 | Yorvipath |
| Corcept Therapeutics | $474.72 | 2019-2024 | Korlym |
| Novo Nordisk INC | $461.15 | 2019-2025 | Sogroya |
| Abbvie INC. | $329.18 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.42 | 2019-2021 | |
| Insulet Corporation | $180.56 | 2019-2021 | |
| Pfizer INC. | $173.80 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $160.19 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $133.19 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $127.33 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $120.73 | 2020-2021 | |
| Antares Pharma, INC. | $113.69 | 2019-2023 | Nocdurna, Tlando, Xyosted |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Grua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.